1 completed, 1 recruiting, 1 withdrawn. 2 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Withdrawn 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Amlodipine placebo: new trials by email Literature Review of Amlodipine placebo trials Research Report on Amlodipine placebo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT Genotype Amlodipine besylate, Amlodipine besylate And Folic Acid, 5-methyltetrahydrofolate (5-MTHF) - Hypertension, MTHFR 677 TT Genotype | Phase 4 | Recruiting | Shenzhen Ausa Pharmed Co.,Ltd | 24000 | 2024-08-22 | 2025-02-26 |
| Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Patients With High Blood Pressure and High Cholesterol Amlodipine, Ezetimibe/Rosuvastatin, Ezetimibe/Rosuvastatin Placebo - Hypertension, Hypercholesterolemia | Phase 3 | Completed | Celltrion Pharm, Inc. | 163 | 2022-08-05 | 2026-05-08 |
| An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine in Participants With Mild/Moderate Essential Hypertension Amlodipine, TCV-116CCB, Amlodipine Placebo - Hypertension | Phase 3 | Withdrawn | Takeda | 2017-05-09 | 2017-06-09 |
Hypertension (3) · Essential Hypertension (1) · Hypercholesterolemia (1) · Ischemic Stroke (1)
Celltrion Pharm, Inc. (1) · Shenzhen Ausa Pharmed Co.,Ltd (1) · Takeda (1)
China (2) · South Korea (1)
PMID 21869730, PMID 22230384, PMID 22880024, PMID 22897803, PMID 25771069, PMID 27834686, PMID 29030456